that its pivotal in Tandem2 Phase 3 clinical trial of sotagliflozin met its primary endpoint of a statistically significant …
Peregrine /quotes/zigman/114805 /quotes/nls/pphm PPHM said its bavituximab medication was used in conjunction with two other medications to treat patients in later stages of lung cancer. While the bavituximab users were able to survive …
Some biotech penny stocks are up as much as 333.9% year to date (YTD), and we've compiled the best-performing biotech penny stocks in 2017 in the list below. Plus, after the list, I'll show you a biotech stock that has the potential to …
Peregrine Pharmaceuticals Inc. (PPHM) has been climbing since the open of trade Friday on above average volume. Shares are now up 0.19 at $0.63. Peregrine Pharmaceuticals has been on an upward trend for the past 2 weeks and …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PPHM at https://www.zacks.com/ap/PPHM
Seattle Genetics Inc. ( SGEN) recently received approval from Health Canada for its oncology drug, Adcetris (brentuximab vedotin). Adcetris has been approved under Health Canada's Notice of Compliance with conditions (NOC/c) for the …
The best-performing penny stock – Zosano Pharma Corp. – soared an incredible 123.3% from Feb. 1 to Feb. 28. To put those gains into perspective, that's more than five times the S&P 500's 23% climb in the last 12 months. Those market …
The stock recorded a trading volume of 1.76 million shares, which was above its three months average volume of 1.51 million shares. The Company's shares are trading below their 50-day moving average by 5.47%. Moreover, shares of …
Our proven model does not conclusively show that Xerox is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. …
Decliners are outpacing advancers 15 to 14 on the New York Stock Exchange Monday. Some 148 stocks hit new 52-week highs on the NYSE, while 10 hit new lows. Decliners are outpacing advancers 13 to 10 on the Nasdaq.